Keith is an accomplished scientist that has channeled 20 years of R&D experience into Biopharma value creation. Most recently, as VP of BD at Insilico Medicine he led asset out-licensing, and as Head of Business Development and Alliance Management at Viridian Therapeutics he led one out-license and three successful in-license processes. Additionally, Keith was responsible for pipeline acquisitions at Boston Pharmaceuticals that are valued at over $2.4B.
As a senior principal scientist at Tesaro (acquired by GSK), Keith led preclinical and translational investigations that supported the global approval of Niraparib/Zejula for ovarian cancer and co-led a team responsible for strategic partnerships to discover novel immuno-oncology therapeutics.
Keith received a Ph.D. in Cell and Developmental Biology from the University of Colorado and did his post-doctoral training at the University of Massachusetts.